Submit Deal

REPLIGEN CORPORATION

Summary

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs.

Deals Overview

Total Deals7

Valued Deals4

Total Value£ 502 M

Avg. Deal Size£ 125 M

Market Context

Senior Management

Olivier Loeillot
President and CEO
Tony J. Hunt
President and CEO
Jon K. Snodgres
CFO

Sort

olivier loeillot

President and CEO at REPLIGEN CORPORATION

Manager

Deal

£ 55 M

Total Value

sondra newman

Global Head of Investor Relations at REPLIGEN CORPORATION

Manager

Deals

£ 164 M

Total Value

kola otitoju

Vice President at REPLIGEN CORPORATION

Manager

Deal

£ 153 M

Total Value

karen dawes

Chairman at REPLIGEN CORPORATION

Manager

Deals

£ 262 M

Total Value

jon k. snodgres

CFO at REPLIGEN CORPORATION

Manager

Deals

£ 262 M

Total Value

tony j. hunt

President and CEO at REPLIGEN CORPORATION

Manager

Deals

£ 447 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy